Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. GVAX vs. Placebo for MDS/AML After Allo HSCT

    ... be "randomized" to receive either GVAX vaccination or placebo (a saline solution) vaccination. Randomization means that you are ... receive the GVAX vaccine and a 50% chance you will receive placebo. Neither you nor your transplant doctor(s) will know which you will be ...

    Clinical Trial last updated 04/28/2016 - 12:01pm.

  2. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and po

    ... Based on the results of this study, the randomized, placebo -controlled phase 3 QUAZAR Lower-Risk MDS trial (AZA-MDS-003) was ... design and rationale for this trial comparing CC-486 with placebo for the treatment of patients with IPSS lower-risk MDS with poor ...

    Research Article last updated 06/23/2016 - 10:17am.

  3. Self-injected PNH therapy on the horizon

    ... most people miss" in the disease is that "there is no placebo response. It doesn't happen" in phase III trials. "We actually have ...

    Article last updated 07/07/2016 - 9:40am.

  4. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    ... 69) or 5 mg/day days 1-28 (n = 69) of 28-day cycles; or placebo (n = 67). Crossover to lenalidomide or higher dose was allowed ... (TI) for ≥ 26 weeks (primary endpoint) versus placebo (56.1% and 42.6% vs 5.9%; both P < .001). Median duration of RBC-TI was ...

    Research Article last updated 07/28/2014 - 9:04am.

  5. Interviews with the Experts: Side Effects of PNH Treatment

    ... receiving eculizumab and 9 (21%) patients receiving placebo (inactive ingredient). Among 193 patients with PNH treated with ...

    Interview last updated 08/31/2016 - 8:37am.

  6. A Combination Study of PF-04449913 and Azacitidine In 1st Line MDS, AML and CMML Patients

    ... This multi center randomized (1:1), double blind, placebo controlled Phase 1b/2 study is designed to compare the safety, ... (PK), and pharmacodynamics (PD) of PF 04449913 or placebo when combined with azacitidine in patients with previously ...

    Clinical Trial last updated 04/27/2016 - 1:20pm.

  7. Effectiveness of lenalidomide in patients over 75 vs. patients under 75 with RBC transfusion-dependent low/int-1-risk MDS and del5q

    ... MDS was recently confirmed in MDS-004, a randomized, placebo -controlled trial, which again demonstrated that lenalidomide ...

    Research Review last updated 05/02/2016 - 9:32am.

  8. A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST)

    ... THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY LOW, LOW, OR ... Drug: Luspatercept Other Name: ACE-536 Other: Placebo ...

    Clinical Trial last updated 04/21/2016 - 1:16pm.

  9. Dr. Vivienne Rebel reviews a recent study about p53 protein levels as a prognostic factor in MDS

    ... trial, for which they received lenalidomide or a placebo .  P53 staining was performed on samples prior to any treatment and ...

    Research Review last updated 05/02/2016 - 9:17am.

  10. Clinical Trial Basics

    ... the new study treatment, the standard treatment, or a placebo . Clinical trials may compare a new medical approach to a standard one that is already available or to a placebo that contains no active ingredients or to no intervention. Some ...

    Page last updated 03/29/2016 - 7:29pm.